ArticlePloS one2019
Phages in a thermoreversible sustained-release formulation targeting E. faecalis in vitro and in vivo.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- CApEsid biOfilm: a suggested pipeline for clinical phage microbiology for biofilm infections based on comparative method study.Scientific reports · 2026Article
- 3D Printing of Bacteriophage-Loaded Hydrogels: Development of a Local and Long-Lasting Delivery System.Advanced healthcare materials · 2026Article
- Bacteriophage Therapy: Overcoming Antimicrobial Resistance Through Advanced Delivery Methods.Molecules (Basel, Switzerland) · 2026Review
- Phage mediated growth inhibition and biofilm disruption of the endodontic pathogen Enterococcus faecalis.PloS one · 2026Article
- Recent perspectives on precision-targeting therapy against oral biofilm.Journal of oral microbiology · 2026Review
- Spot-on phage therapy: stable formulations, smarter dosing for topical phage application.Frontiers in cellular and infection microbiology · 2026Review
- Insights into ecology, pathogenesis, and biofilm formation ofMicrobiology and molecular biology reviews : MMBR · 2025Review
- Bacteriophage entrapment strategies for the treatment of chronic wound infections: a comprehensive review.Archives of microbiology · 2024Review
- A review and new perspective on oral bacteriophages: manifestations in the ecology of oral diseases.Journal of oral microbiology · 2024Review
- The applications of animal models in phage therapy: An update.Human vaccines & immunotherapeutics · 2023Review
- The Combination of Antibiotic and Non-Antibiotic Compounds Improves Antibiotic Efficacy against Multidrug-Resistant Bacteria.International journal of molecular sciences · 2023Review
- Bacteriolytic Potential ofViruses · 2023Article
- Advancements in bacteriophage therapies and delivery for bacterial infection.Materials advances · 2023Review
- Phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens.Frontiers in medicine · 2023Review
- Article
- What Are the Potential Benefits of Using Bacteriophages in Periodontal Therapy?Antibiotics (Basel, Switzerland) · 2022Review
- Anti-biofilm Activity of a Lytic Phage Against Vancomycin-ResistantIranian journal of pathology · 2022Article
- Phage Therapy as a Focused Management Strategy in Aquaculture.International journal of molecular sciences · 2021Review
- Phage TargetingAntibiotics (Basel, Switzerland) · 2021Article
- Encapsulation and Delivery of Therapeutic Phages.Applied and environmental microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEnterococcus faecalis is a key pathogen recovered from root canals when conventional treatment fails. Phage therapy has generated new interest in combating pathogens. A sustained-release formulation using specific phages against E. faecalis may offer an alternative approach.
objectivesTo evaluate the efficacy of anti-E. faecalis phages formulated in a thermo- sustained-release system against E. faecalis in vitro and in vivo.
methodsEFDG1 and EFLK1 phages were formulated with poloxamer P407. Gelation time, phage survival, activity and toxicity were evaluated. Lytic activity was evaluated in vitro against E. faecalis at various growth phases, including anti-biofilm activity. Methods included viable bacterial count (CFU/mL), biofilm biomass determination and electron microscopy (live/dead staining). Further evaluation included infected incisors in an in vivo rat model. Anti-E. faecalis phage-cocktail suspension and sustained-release phage formulation were evaluated by viable bacterial count (CFU/mL), histology, scanning electron microscopy (SEM) and 16S genome sequencing of the microbiota of the root canal.
resultsGelation time for clinical use was established. Low toxicity and a high phage survival rate were recorded. Sustained-release phages reduced E. faecalis in logarithmic (4 logs), stationary (3 logs) and biofilm (4 logs) growth phases. Prolonged anti-biofilm activity of 88% and 95% reduction in biomass and viable counts, respectively, was recorded. Reduction of intracanal viable bacterial counts was observed (99% of enterococci) also seen in SEM. Phage treatment increased Proteobacteria and decreased Firmicutes. Histology showed reduced periapical inflammation and improved healing following phage treatment.
conclusionPoloxamer P407 formulated with phages has an effective and long-lasting effect in vitro and in vivo targeting E. faecalis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.